Aconcagua Bio Inc. has divulged new calcitonin (CALCR; CT-R) and amylin receptor agonists intended for use in the treatment of pain, neurodegeneration, bone, metabolic and cardiovascular disorders.

Ascletis Pharma Inc. has selected ASC-36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor peptide agonist, as a clinical development candidate.

Aconcagua Bio Inc. has synthesized calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone disease, periodontal disease, metabolic dysfunction-associated steatotic liver disease MASLD), osteogenesis imperfecta and cardiovascular disorders, among others.

Viking Therapeutics Inc. has identified amylin analogues acting as calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of diabetes and obesity.

Amylin is an attractive target in the management of obesity, since it is a peptide hormone co-secreted with insulin in response to food intake, and suppresses appetite and delays gastric emptying. At the American Diabetes Association's Scientific Sessions in Chicago, Structure Therapeutics Inc. presented data regarding the dual amylin receptor and calcitonin receptor agonist ACCG-2671 for obesity treatment.

Aconcagua Bio Inc. has divulged calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone and cardiovascular disorders.

Eli Lilly & Co. has synthesized macrocyclic peptides acting as amylin receptor agonists, glucose- and/or triglyceride-lowering agents reported to be useful for the treatment of type 2 diabetes, obesity, dyslipidemia and nonalcoholic steatohepatitis.